Agilent Technologies Inc (A)

Wie das Geld verdient wird

Agilent earns money in two ways, and the 10-K splits revenue accordingly: product revenue — analytical instruments, software and consumables — was $4,944 million in fiscal 2025, while services and other revenue was $2,004 million, out of $6,948 million total. Instruments are capital equipment bought in lumpy cycles; around that installed base the company sells columns, reagents, supplies, spare parts, repairs, maintenance and compliance contracts, plus software and lab-automation solutions. The company states that its service and consumables businesses are mostly recurring in nature and less exposed to seasonality and industry cycles than the instrument businesses, and that much of the CrossLab consumables portfolio is vendor-neutral, so it can be sold to labs that bought a competitor's instrument. Selling is mostly through a direct sales force, supplemented by resellers, distributors, sales agents and e-commerce.

Umsatz nach Segment

Agilent's advantage rests on the instruments already installed in customers' labs. Once a chromatograph or mass spectrometer is in place, the lab buys columns, reagents, supplies, spare parts, service contracts and instrument-control software around it, and in pharmaceutical quality-control environments the analytical method is validated against that specific instrument and software, so changing vendor means revalidating work under regulatory scrutiny. That is why the recurring services and consumables business is the largest of the three segments. The limit on the moat is visible in the filing itself: Agilent describes its markets as characterised by evolving standards and intense competition against Thermo Fisher, Danaher, Waters, Bruker, Shimadzu and PerkinElmer, competing on performance, support and price — and much of its own CrossLab consumables portfolio is deliberately vendor-neutral, which is an admission that consumables can be bought from someone other than the instrument maker.

Agilent's demand has two different rhythms. The instrument side is capital equipment: labs buy it when budgets allow, so it follows pharmaceutical capital-expenditure cycles, chemicals and semiconductor capex, and public research funding — the company itself discloses that demand for some products depends on customers' capital spending policies, R&D budgets and government funding. That is what fiscal 2024 looked like: group revenue fell 5% to $6,510 million as customers held back on equipment. The other side is the installed base: once instruments are in the lab, they need columns, reagents, parts, repairs and compliance service whether or not new equipment is being bought, and the company states this service and consumables business is mostly recurring and less susceptible to seasonality and industry cycles. Services and other revenue grew 3% in fiscal 2024, the same year product revenue fell 7%. The end markets also differ: pharmaceutical quality control, clinical diagnostics and food and environmental testing are regulation-driven and steadier, while chemicals, advanced materials and semiconductors move with their own industrial cycles.

Wichtigste Risiken

• Demand depends on customers' capital spending, R&D budgets and government funding — Agilent discloses that demand for some of its products and services depends on the capital spending policies of its customers, on their research and development budgets, and on government funding policies. In fiscal 2024 the company saw revenue decline in its Life Sciences and Diagnostics Markets and Applied Markets segments because of pressure on customers' capital expenditure.
• Failure to introduce successful new products in time — The company states that if it does not introduce successful new products and services in a timely manner — in markets marked by frequent new-product introductions, rapid technological change and changing industry standards — its products and services may become obsolete and its operating results may suffer.
• International exposure and currency — Agilent flags economic, political, foreign-currency and other risks tied to international sales and operations as capable of adversely affecting its results, and separately warns that recent and dynamic government rule-making and policy changes could raise costs and affect its markets and customers.
• Regulatory approval and FDA oversight — Part of the portfolio — pathology, companion diagnostics, the CDMO operations — is subject to extensive regulation by the FDA and similar foreign agencies. The company warns that failure to comply could harm its reputation, business and financial condition, and that compliance with or changes in such regulations may force product recalls or a halt to manufacturing.
• Acquisitions may not deliver what was expected — Agilent discloses that its acquisitions, strategic investments, alliances, joint ventures, business exits and divestitures may produce financial results different from those expected. The fiscal 2023 exit of the Resolution Bioscience business carried a $258 million intangible impairment, and the BIOVECTRA acquisition added $526 million of goodwill in fiscal 2024.
• Manufacturing capacity, supply chain and outsourcing — The company warns that results may suffer if manufacturing capacity does not match demand, that consolidating and streamlining manufacturing may not deliver the expected efficiencies and could disrupt deliveries, and that dependence on contract manufacturing, outsourced logistics and third-party delivery may affect its ability to bring products to market.
• Information systems and cybersecurity — Agilent states that a significant disruption or security breach of its information technology systems, or a failed implementation of new systems and software, could adversely affect the business. It also flags risks from the development and use of artificial intelligence in its operations, services and products, including reputational harm, regulatory action and legal liability.
• Debt and dividend are not guaranteed — The company discloses that it has outstanding debt and may incur more, which could adversely affect its financial condition, liquidity and results, and states plainly that it cannot assure it will continue to pay dividends on its common stock. Interest expense was $112 million in fiscal 2025 against $96 million in fiscal 2024.

The 10-K does not disclose what share of revenue the largest customers represent. What it does say points to a very fragmented base: roughly 22,200 customers in Life Sciences and Diagnostics Markets, about 59,700 in Agilent CrossLab and about 17,200 in Applied Markets during fiscal 2025, spread across pharmaceutical, clinical, academic, chemical, food, environmental and forensic end markets. On credit risk the company states that no single customer accounted for more than 10 percent of accounts receivable as of 31 October 2025 or 2024, and describes its receivable risk as diversified across many industries and geographies. Note this is a statement about receivables, not about revenue.